Its a NEW Year, New Management, I am looking forward to a great year and some updates on
Cebidiofen is a provisional patent pending, product formulations (USPTO Patent Pending Application No. 62464442
and
Polyoxyfen is a provisional patent pending, product formulations (USPTO Patent Pending Application No. 62464423)
The potential use of this for Opiate withdrawal OR an alternative to Opiates in the first place is epic, BOTH is even better.
I personally dont see them on the Pinks long, its a great place for venture and other initial capital raises but long term the next step of course is migrate and uplist or get bought out by a major after clinical trials and the other usual process are initiated or completed.
In my opinion, Any way you look at HADV, the "UPSIDE Potential" is great!!
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM